USA Medical Scientist Awarded National Grant

The University of South Alabama (USA) has announced that its scientist Dr. Michael R. Elliott recently received a two-year R21 grant for $431,147 from the National Institute of Allergy and Infectious Diseases. Elliott’s goal is to provide new insights aimed at helping patients with cancer and autoimmune diseases avoid and better treat first infusion reactions. “Antibody-based therapies are among the most powerful tools for treating cancer and autoimmune diseases,” he said. “Yet for some patients, the very first infusion of these therapies can trigger inflammatory reactions ranging from mild discomfort to severe complications.” Elliott is an associate professor in the Department of Microbiology and Immunology at USA’s Frederick P. Whiddon College of Medicine. His research aims to uncover the biological triggers of inflammatory reactions, with a particular focus on the immune cells that drive them. He hopes that, by identifying the underlying mechanisms, these therapies will be made safer and more widely accessible to patients.

Read More

Public Safety Fair Coming To Robertsdale

Public Safety Fair Coming To Robertsdale

UM Hires Mitchell As Communications Director

UM Hires Mitchell As Communications Director

Hargrove To Host Downtown Get Down On September 24

Hargrove To Host Downtown Get Down On September 24

Dragons On The Delta Boat Race Announced

Dragons On The Delta Boat Race Announced

Funding Growth Workshop Coming To Mobile Chamber

Funding Growth Workshop Coming To Mobile Chamber

Summer Work Travel Community Forum Coming To Orange Beach

Summer Work Travel Community Forum Coming To Orange Beach

Joe Jefferson Players To Present Frozen

Joe Jefferson Players To Present Frozen

Loyola Art Show Coming Up

Loyola Art Show Coming Up

SALT’S Sip & Sprout Coming Up

SALT’S Sip & Sprout Coming Up

Subscribe to our weekly newsletter

Sign up here for free to get Bay Business News email newsletter every Friday.

By subscribing, you agree to our User Agreement and Privacy Policy & Cookie Statement.

Something went wrong. Please check your entries and try again.